On October 20, 2026, Nanobiotix S.A. issued a report detailing its voting rights and shares capital as of September 30, 2026. This update is significant as it sheds light on the company’s governance structure and the engagement of its shareholders.

Nanobiotix S.A. is a late-stage clinical biotechnology company based in Paris, France, specializing in innovative therapeutic approaches within the pharmaceutical preparations sector. The company is publicly traded on both Euronext Paris and the Nasdaq under the tickers NBTX and NNBXF. Incorporated in 2003, Nanobiotix has established itself as a pioneer in nanotechnology applications, particularly in oncology and central nervous system disorders.

The filing notes that as of September 30, 2026, Nanobiotix had a total of 50,967,610 shares outstanding. The report also specifies the total number of voting rights, with 54,729,543 theoretical voting rights and 54,707,425 exercisable voting rights. This information is crucial for shareholders as it reflects the company’s governance and the power of shareholders in decision-making processes.

This update may affect various stakeholders, including current and potential investors, analysts, and regulatory bodies, as it provides transparency regarding the company's capital structure and governance practices. Such disclosures are vital for maintaining investor confidence and ensuring compliance with regulatory requirements.

The filing does not say what happens next regarding future updates or shareholder meetings, but it emphasizes Nanobiotix’s commitment to keeping its shareholders informed and engaged.